Investigation in a murine model of possible mechanisms of enhanced local reactions to post-primary diphtheria-tetanus toxoid boosters in recipients of acellular pertussis-diphtheria-tetanus vaccine

References

• Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1984; 1:122 - 6; http://dx.doi.org/10.1016/S0140-6736(84)90061-8; PMID: 6140441
   PubMed Web of Science ®Google Scholar
• Kimura M, Hikino N. Results with a new DTP vaccine in Japan. Dev Biol Stand 1985; 61:545 - 61; PMID: 2872131
   PubMedGoogle Scholar
• Kimura M, Kuno-Sakai H. Experiences with acellular pertussis vaccine in Japan and epidemiology of pertussis. Tokai J Exp Clin Med 1987; 12:263 - 73; PMID: 3508651
   PubMedGoogle Scholar
• Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 85:385 - 400; PMID: 20939150
   PubMedGoogle Scholar
• Kimura M, Kuno-Sakai H. Pertussis vaccines in Japan. Acta Paediatr Jpn 1988; 30:143 - 53; http://dx.doi.org/10.1111/j.1442-200X.1988.tb02512.x; PMID: 3149848
   PubMedGoogle Scholar
• Kamiya H, Nii R. Overview of currently available Japanese acellular pertussis vaccines and future problems. Tokai J Exp Clin Med 1988; 13:Suppl 45 - 9; PMID: 3273618
   PubMedGoogle Scholar
• Gold MS, Noonan S, Osbourn M, Precepa S, Kempe AE. Local reactions after the fourth dose of acellular pertussis vaccine in South Australia. Med J Aust 2003; 179:191 - 4; PMID: 12914508
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Remple VP, Macnabb J, Pielak K, Patrick DM, Halperin SA, Scheifele D. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics 2003; 112:e453; http://dx.doi.org/10.1542/peds.112.6.e453; PMID: 14654644
   PubMed Web of Science ®Google Scholar
• Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, Anderson EL, Steinhoff MC, Edwards KM. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000; 105:e12; http://dx.doi.org/10.1542/peds.105.1.e12; PMID: 10617749
   PubMed Web of Science ®Google Scholar
• Iwasa S, Ishida S, Asakawa S, Akama K. A curious histamine-sensitizing activity shown by the newly-developed Japanese acellular pertussis vaccine. Dev Biol Stand 1985; 61:453 - 60; PMID: 3835082
   PubMedGoogle Scholar
• Ministry of Health, Labour and Welfare, Japanese Government. Minimum Requirements for Biological Products; 2004. Available from: http://www.niid.go.jp/niid/ja/mrbp.html
   Google Scholar
• Horiuchi Y, Takahashi M, Konda T, Ochiai M, Yamamoto A, Kataoka M, Toyoizumi H, Arakawa Y. Quality control of diphtheria tetanus acellular pertussis combined (DTaP) vaccines in Japan. Jpn J Infect Dis 2001; 54:167 - 80; PMID: 11754154
   PubMed Web of Science ®Google Scholar
• Okada K, Ueda K, Morokuma K, Fukushige J, Miyazaki C. Comparison of antibody titers in eleven- to twelve-year old Japanese school children six years after administration of acellular and whole cell pertussis vaccines combined with diphtheria-tetanus toxoids. Pediatr Infect Dis J 1998; 17:1167 - 9; http://dx.doi.org/10.1097/00006454-199812000-00016; PMID: 9877371
   PubMed Web of Science ®Google Scholar
• Tamura M, Nogimori K, Murai S, Yajima M, Ito K, Katada T, Ui M, Ishii S. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 1982; 21:5516 - 22; http://dx.doi.org/10.1021/bi00265a021; PMID: 6293544
   PubMed Web of Science ®Google Scholar
• Katada T, Ui M. Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc Natl Acad Sci U S A 1982; 79:3129 - 33; http://dx.doi.org/10.1073/pnas.79.10.3129; PMID: 6954463
   PubMed Web of Science ®Google Scholar
• Tamura M, Nogimori K, Yajima M, Ase K, Ui M. A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells. J Biol Chem 1983; 258:6756 - 61; PMID: 6343381
   PubMed Web of Science ®Google Scholar
• Ui M. In: Moss J, Vaughan M, editors. ADP-ribosylating toxins and G protein. Washington, D.C.: American Society for Microbiology; 1990. p. 45-77.
   Google Scholar
• World Health Organization. Recommendations to assure the quality, safety and efficacy of acellular pertussis vaccines; 2013. Technical Report Series 979, Annex 4.
   Google Scholar
• European Pharmacopoeia. Suppl. 7.8, Methods of Analysis 07/2013:20633: Residual pertussis toxin and irreversibility of pertussis toxoid. Strasbourg: Council of Europe; 2013.
   Google Scholar
• Yamamoto A, Nagata N, Ochiai M, Kataoka M, Toyoizumi H, Okada K, Horiuchi Y. Enhanced sensitisation of mice with diphtheria tetanus acellular pertussis vaccine to local swelling reaction to the booster immunisation. Vaccine 2002; 20:3088 - 94; http://dx.doi.org/10.1016/S0264-410X(02)00290-6; PMID: 12163259
   PubMed Web of Science ®Google Scholar
• Finck-Barbançon V, Barbieri JT. ADP-ribosylation of alpha i3C20 by the S1 subunit and deletion peptides of S1 of pertussis toxin. Biochemistry 1995; 34:1070 - 5; http://dx.doi.org/10.1021/bi00003a043; PMID: 7827022
   PubMed Web of Science ®Google Scholar
• Cyr T, Menzies AJ, Calver J, Whitehouse LW. A quantitative analysis for the ADP-ribosylation activity of pertussis toxin: an enzymatic-HPLC coupled assay applicable to formulated whole cell and acellular pertussis vaccine products. Biologicals 2001; 29:81 - 95; http://dx.doi.org/10.1006/biol.2001.0280; PMID: 11580213
   PubMed Web of Science ®Google Scholar
• Yuen CT, Canthaboo C, Menzies JA, Cyr T, Whitehouse LW, Jones C, Corbel MJ, Xing D. Detection of residual pertussis toxin in vaccines using a modified ribosylation assay. Vaccine 2002; 21:44 - 52; http://dx.doi.org/10.1016/S0264-410X(02)00446-2; PMID: 12443661
   PubMed Web of Science ®Google Scholar
• Gomez SR, Xing DKL, Corbel MJ, Coote J, Parton R, Yuen C-T. Development of a carbohydrate binding assay for the B-oligomer of pertussis toxin and toxoid. Anal Biochem 2006; 356:244 - 53; http://dx.doi.org/10.1016/j.ab.2006.05.012; PMID: 16782039
   PubMed Web of Science ®Google Scholar
• Yuen CT, Horiuchi Y, Asokanathan C, Cook S, Douglas-Bardsley A, Ochiai M, Corbel M, Xing D. An in vitro assay system as a potential replacement for the histamine sensitisation test for acellular pertussis based combination vaccines. Vaccine 2010; 28:3714 - 21; http://dx.doi.org/10.1016/j.vaccine.2010.03.009; PMID: 20307594
   PubMed Web of Science ®Google Scholar
• Kimura M, Kuno-Sakai H. Developments in pertussis immunisation in Japan. Lancet 1990; 336:30 - 2; http://dx.doi.org/10.1016/0140-6736(90)91530-N; PMID: 1973217
   PubMed Web of Science ®Google Scholar
• Sato Y, Sato H. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers. Tokai J Exp Clin Med 1988; 13:Suppl 79 - 88; PMID: 2908530
   PubMedGoogle Scholar
• Burns DL, Kenimer JG, Manclark CR. Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology. Infect Immun 1987; 55:24 - 8; PMID: 3539804
   PubMed Web of Science ®Google Scholar
• Ibsen PH. The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine 1996; 14:359 - 68; http://dx.doi.org/10.1016/0264-410X(95)00230-X; PMID: 8735545
   PubMed Web of Science ®Google Scholar
• Kataoka M, Yamamoto A, Ochiai M, Harashima A, Nagata N, Hasegawa H, Kurata T, Horiuchi Y. Comparison of acellular pertussis-based combination vaccines by Japanese control tests for toxicities and laboratory models for local reaction. Vaccine 2009; 27:1881 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.01.095; PMID: 19368767
   PubMed Web of Science ®Google Scholar
• Francotte M, Locht C, Feron C, Capiau C, De Wilde M. Monoclonal antibodies specific for pertussis toxin subunits and identification of the haptoglobin-binding site. In: Lerner RA, Ginsberg H, Chanock RM, Brown F, editors. Vaccines 89. Plainview, NY: Cold Spring Harbor Laboratory Press; 1989. p. 243-7.
   Google Scholar
• Loosmore S, Zealey G, Cockle S, Boux H, Chong P, Yacoob R, Klein M. Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits. Infect Immun 1993; 61:2316 - 24; PMID: 8500874
   PubMed Web of Science ®Google Scholar
• Stein PE, Boodhoo A, Armstrong GD, Heerze LD, Cockle SA, Klein MH, Read RJ. Structure of a pertussis toxin-sugar complex as a model for receptor binding. Nat Struct Biol 1994; 1:591 - 6; http://dx.doi.org/10.1038/nsb0994-591; PMID: 7634099
   PubMedGoogle Scholar
• Lobet Y, Feron C, Dequesne G, Simoen E, Hauser P, Locht C. Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin. J Exp Med 1993; 177:79 - 87; http://dx.doi.org/10.1084/jem.177.1.79; PMID: 8418210
   PubMed Web of Science ®Google Scholar
• Saukkonen K, Burnette WN, Mar VL, Masure HR, Tuomanen EI. Pertussis toxin has eukaryotic-like carbohydrate recognition domains. Proc Natl Acad Sci U S A 1992; 89:118 - 22; http://dx.doi.org/10.1073/pnas.89.1.118; PMID: 1729677
   PubMed Web of Science ®Google Scholar
• Millen SH, Lewallen DM, Herr AB, Iyer SS, Weiss AA. Identification and characterization of the carbohydrate ligands recognized by pertussis toxin via a glycan microarray and surface plasmon resonance. Biochemistry 2010; 49:5954 - 67; http://dx.doi.org/10.1021/bi100474z; PMID: 20515023
   PubMed Web of Science ®Google Scholar
• Scheifele DW, Ochnio JJ, Halperin SA. Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens. Pediatr Infect Dis J 2009; 28:985 - 9; http://dx.doi.org/10.1097/INF.0b013e3181a9cc2a; PMID: 19755930
   PubMed Web of Science ®Google Scholar
• Ryan M, McCarthy L, Rappuoli R, Mahon BP, Mills KH. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int Immunol 1998; 10:651 - 62; http://dx.doi.org/10.1093/intimm/10.5.651; PMID: 9645613
   PubMed Web of Science ®Google Scholar
• Xing D, Das RG, Newland P, Corbel M. Comparison of the bioactivity of reference preparations for assaying Bordetella pertussis toxin activity in vaccines by the histamine sensitisation and Chinese hamster ovary-cell tests: assessment of validity of expression of activity in terms of protein concentration. Vaccine 2002; 20:3535 - 42; http://dx.doi.org/10.1016/S0264-410X(02)00338-9; PMID: 12297399
   PubMed Web of Science ®Google Scholar
• Gomez SR, Yuen CT, Asokanathan C, Douglas-Bardsley A, Corbel MJ, Coote JG, Parton R, Xing DK. ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitisation test. Vaccine 2007; 25:3311 - 8; http://dx.doi.org/10.1016/j.vaccine.2007.01.009; PMID: 17287049
   PubMed Web of Science ®Google Scholar
• Ishida S, Kurokawa M, Asakawa S, Iwasa S. A sensitive assay method for the histamine-sensitizing factor using change in rectal temperature of mice after histamine challenge as a response. J Biol Stand 1979; 7:21 - 9; http://dx.doi.org/10.1016/S0092-1157(79)80034-7; PMID: 489619
   PubMedGoogle Scholar
• Finney DJ. Statistical methods in biological assay. 3rd ed. London: Charles Griffin Co. Ltd; 1978.
   Google Scholar